# ImmunityBio (IBRX) — News

IBRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ibrx/news

## Recent headlines

- [US FDA - Expands indication for Nogapendekin Alfa in Bakicept-Pmln to high-grade papillary-only NMIBC](https://www.ainvest.com/news/fda-expands-indication-nogapendekin-alfa-bakicept-pmln-high-grade-papillary-nmibc-2610) — AInvest Wire, Oct 14, 2026
  The U.S. Food and Drug Administration (FDA) has initiated a regulatory review to expand the indication for Nogapendekin Alfa Inbakicept (ANKTIVA) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of high-grade papillary-only non-muscle invasive bladder cancer (NMIBC) that is…
- [FDA expands Altor's Ankitva use to papillary bladder cancer](https://www.ainvest.com/news/fda-expands-altor-ankitva-papillary-bladder-cancer-2610) — AInvest Wire, Oct 14, 2026
  The U.S. Food and Drug Administration (FDA) has received a supplemental biologics license application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva), expanding its potential use to treat patients with Bacillus Calmette–Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC)…
- [Fibra Macquarie technical committee says Fibra MTY offer fair](https://www.ainvest.com/news/fibra-macquarie-technical-committee-fibra-mty-offer-fair-2610) — AInvest Wire, Oct 13, 2026
  Fibra Macquarie’s technical committee has concluded that the offer from Fibra MTY is fair, marking a key step in the ongoing merger process. The proposed transaction, valued at approximately $6.5 billion, would combine two major real estate investment trusts in Mexico, creating one of the country’s…
- [ImmunityBio (IBRX) shares dropped 6.94% intraday, reversing a 9.94% surge on Sept. 23.](https://www.ainvest.com/news/immunitybio-ibrx-shares-dropped-6-94-intraday-reversing-9-94-surge-sept-23-2609) — AInvest Wire, Sep 23, 2026
  ImmunityBio (NASDAQ: IBRX) shares fell 6.94% intraday on Sept. 23, reversing a 9.94% surge from the previous day. The decline followed a warning letter from the U.S. Food & Drug Administration (FDA) regarding misleading promotional materials for Anktiva . The FDA cited a television advertisement…
- [ImmunityBio appoints Dr. Jim Yong Kim, former World Bank president and global health leader, as vice chairman](https://www.ainvest.com/news/immunitybio-appoints-dr-jim-yong-kim-world-bank-president-global-health-leader-vice-chairman-2608) — AInvest Wire, Aug 10, 2026
  ImmunityBio, a biotechnology company focused on developing innovative immunotherapies, has appointed Dr. Jim Yong Kim as vice chairman. Dr. Kim, a former president of the World Bank and a globally recognized leader in public health, brings extensive experience in global development and…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).